Novo Nordisk


Zuellig Pharma
Concise Prescribing Info
An adjunct to a reduced-calorie diet & increased physical activity for wt management in adults w/ an initial BMI of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea. An adjunct to a healthy nutrition & increased physical activity for wt management in adolescents ≥12 yr w/ obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points) & body wt >60 kg.
Dosage/Direction for Use
SC Adult & adolescent 12-18 yr Initially 0.6 mg once daily, should be increased to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk interval. Maintenance: 3 mg daily.
May be taken with or without food.
Hypersensitivity. Patients w/ personal or family history of medullary thyroid carcinoma or in patients w/ multiple endocrine neoplasia syndrome type 2.
Special Precautions
Not to be administered IV or IM. Not to be used as substitute for insulin in patients w/ DM. Discontinue treatment after 12 wk on 3 mg daily dose if adult patients have not lost at least 5%, & in adolescents ≥12 yr at least 4% of initial BMI. Discontinue & not to be restarted treatment if pancreatitis & acute pancreatitis is confirmed. Discontinue treatment in patients who experienced a clinically relevant sustained increase in resting heart rate. Increased risk of cholelithiasis & cholecystitis; hypoglycaemia in patients w/ type 2 DM. Not recommended in patients w/ CHF NYHA class IV; treated w/ other products for wt management; obesity secondary to endocrinological or eating disorders or to treatment w/ medicinal products causing wt gain; inflammatory bowel disease & diabetic gastroparesis. Patients w/ thyroid disease. Potential risk of dehydration in relation to GI side effects. Avoid fluid depletion. Self-monitor blood glucose in reducing dose of insulin or insulin secretagogues. Monitor heart rate at regular intervals. Not to be used in combination w/ another GLP-1 receptor agonist. Reduce dose in concomitant administration w/ insulin or insulin secretagogues eg, sulfonylureas. May affect ability to drive & use machines. Not recommended in patients w/ severe renal impairment (CrCl <30 mL/min); ESRD; severe hepatic impairment. Not to be used during pregnancy & lactation. Not recommended to administer >3 mg daily doses in adolescents >12 yr. Childn <12 yr. Not recommended in elderly ≥75 yr.
Adverse Reactions
Nausea, vomiting, diarrhoea, constipation. Hypoglycaemia; insomnia; dizziness, dysgeusia; dry mouth, dyspepsia, gastritis, GERD, upper abdominal pain, flatulence, eructation, abdominal distension; cholelithiasis; inj site reactions, asthenia, fatigue; increased lipase & amylase.
Drug Interactions
Reduced AUC & decreased Cmax of digoxin & lisinopril. Lowered Cmax of ethinylestradiol, levonorgestrel. Monitor INR w/ warfarin or other coumarin derivatives.
MIMS Class
Anti-Obesity Agents / Antidiabetic Agents
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Saxenda soln for inj 6 mg/mL
((3 mL)) 3's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in